2 Min Read
** Drugmaker's shares down 33.4 pct at $17.79 premarket; set to open at near 7-year low
** Multiple brokerages cut PT and rating after company slashes 2016 revenue and profit forecast to reflect operating challenges in its legacy generic business and pressures on a few of its core brand products
** Leerink cuts Endo's rating to "market perform" from "outperform", Mizuho to "underperform" from "neutral", Piper Jaffray to "neutral" from "overweight"
** Mizuho analysts say they view stock as "toxic," while RBC analysts say they think Endo needs to look at strategic alternatives at this point
** Lowering of guidance was not the surprise, but the magnitude was, Cowen & Co analysts write. "The question remains whether Endo can stabilize its core operations and begin to generate meaningful cash yield."
** Other specialty drugmakers such as Horizon Pharma Plc and Mallinckrodt Plc and Valeant Pharmaceuticals International Inc also fall
** Capital Research Global Investors is top shareholder, was buying in, owned 23 million shares as of March 31. That's about 10 pct of the company's shares outstanding
** 10 out of 20 brokerages, rate stock "buy" or higher, remaining "hold"; median PT $45
** Up to Thursday's close, stock had lost more than half of its value this year